Shares of BioMimetic Therapeutics (Ticker: BMTI) are up more than 3 percent in Thursday morning trading after the Franklin-based company said it has launched a clinical trial to test its treatment for lateral epicondylitis, better know as tennis elbow. BioMimetic is now up about 6 percent since Wright Medical said it would buy the company in mid-November.